mardi 16 juin 2020

Onco Actu du 16 juin 2020

CICERO software enables detection of cancer-causing gene fusions [St. Jude Children’s Research Hospital] 
In developing CICERO, Zhang and her colleagues took advantage of a technology called RNA sequencing. Using this technique, they analyzed cancer cells to detect fusion events. CICERO distinguishes fusion events by comparing the cells’ RNA sequence, called the “transcriptome,” with the published reference version of the DNA sequence of the human genome.

Drug with new approach on impeding DNA repair shows promise in first clinical trial [Dana-Farber Cancer Institute] 
The findings may set the stage for testing berzosertib – an inhibitor of the ATR protein – in a range of other cancers, investigators say.

Eli Lilly's R&D revolving door spins again as Gandhi heads back to Dana-Farber [Fierce Biotech] 
Gandhi, a thoracic oncologist, was tapped in April 2018 to head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.

Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work [Fierce Biotech] 
Shattuck has previously said it can create single molecules that not only block immune checkpoints like PD-1/PD-L1 to remove a brake on the immune system but also simultaneously encourage T cells to attack malignant cells. The result is “combination immunotherapy with a single product.”

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online [Fierce Pharma] 
After years in the works, Gilead's 117,000-square-foot CAR-T facility at SEGRO Park Amsterdam Airport is now fully operational after the European Medicines Agency (EMA) approved the plant's end-to-end manufacturing process late last week. 

Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations [NCI] 
The drug’s approval was based on a study in which it shrank tumors in more than half of all patients with advanced RET-altered lung and thyroid cancers, in many cases for 6 months or longer.

Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer [Jazz Pharmaceuticals] 
Zepzelca is approved under accelerated approval based on overall response rate and duration of response demonstrated in an open-label, monotherapy clinical trial.

Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug [Xconomy] 
Madrid-based PharmaMar, which developed lurbinectedin (Zepzelca), licensed its US commercialization rights to Jazz Pharmaceuticals last December.

Entrectinib is recommended, within its marketing authorisation, as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors. It is recommended only if the company provides entrectinib according to the commercial arrangement.

Rozlytrek is set for approval in the EU during the next few weeks after a positive opinion from the European Medicines Agency’s CHMP. It is estimated that this treatment will be made available to around 412 people in England.

Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate.

COVID-19: Keeping patients on cancer clinical trials [Cancer Research UK] 
It’s clear that the impact of COVID-19 on cancer trials will be felt for many years to come. Data collection has been affected, which means that clinical trials that have been paused will take a while to get back on their feet.